The client was building a new kind of biotech company around a new manufacturing challenge: moving mRNA innovation into GMP manufacturing with unprecedented urgency.
Case Study
70% acceleration to manufacturing phase
$5.6M+ in CapEx savings from individual site builds
7K+ hours of operator wait time removed per year
An unprecedented need for speed
The client was building a new kind of biotech company around a new manufacturing challenge: moving mRNA innovation into GMP manufacturing with unprecedented urgency. The immediate requirement was to stand up a digital plant model that could support production of a single high-priority product while maintaining the quality, traceability, speed, and control required in regulated manufacturing.
The first phase was about speed and alignment. The client needed to put MES in the cloud and connect it to plant-floor systems, DCS, historian, and digital records quickly enough to support urgent manufacturing timelines. The challenge was not just technical. To meet demand, the client had partnered with an established global biopharma manufacturer, creating a two-site operating model that combined a newly built biotech facility with an existing large-scale manufacturing site. This required alignment between two manufacturing sites with very different operating cultures: one moving with the urgency of a digital biotech, the other operating with the risk discipline of large-scale manufacturing.
After the first digital plants began operating, the requirements evolved. The initial environment had been optimized to deliver a single product with one recipe under extraordinary time pressure. The pace required was extraordinary: the vaccine candidate emerged in roughly two weeks. Now the client still needed to translate that breakthrough into a manufacturable, compliant, digitally enabled production model fast enough to meet global demand.
This expansion of capability to support global delivery required a different model: creating a repeatable manufacturing platform capable of supporting any recipe, multiple products, and multiple sites.
Challenge
- Stand up a compliant digital plant fast enough for urgent manufacturing timelines
- Align two manufacturing sites with very different operating cultures
Strategy designed for efficient execution
Stellix helped power the first digital manufacturing stack by connecting cloud-based MES with the plant-floor systems, DCS, historian, and digital execution capabilities required to support GMP manufacturing. The work helped turn an ambitious digital plant vision into working regulated production systems under extreme timeline pressure.
In that first phase, Stellix’s role was not only technical. The team helped create the focus and alignment required for quick, efficient execution across organizations, functions, and sites. Stellix translated the customer’s digital manufacturing strategy into practical decisions and working systems, helping the customer and its manufacturing partner move fast enough to meet the moment.
This strength drew on the unique ways Stellix works. The team helped develop strategy with the customer in a way that made sure it stayed closely tied to execution. Unlike advisory models that separate planning from implementation, or systems integration models that wait for the customer to define every requirement, Stellix helped shape the path and then made it real.
As the client moved into this next phase, Stellix helped re-engineer the plant model for scale. The technical shift was from MES in the cloud to a broader “everything in the cloud” architecture that supported a more standardized, supportable digital manufacturing environment that could extend across sites, countries, and operating models.
That meant selecting the right design approach to deliver on phase objectives. The global model required a reusable platform: standardized recipe structures, consistent MES and DCS patterns, shared data architecture, and support models that could be replicated across sites so new facilities could be deployed and operated using the processes, tools, and practices established at the launch site.
Stellix brought MES and plant-floor subject matter expertise, global digital run support, and enterprise manufacturing experience to help define that transition. The team helped connect the launch site with global manufacturing expansion, creating a clearer path for repeatable deployment, support, and continuous improvement across multiple geographies.
Stellix Role
- Connected cloud MES with plant-floor systems, DCS, historian, and digital records for GMP manufacturing
- Defined standardized recipes, MES and DCS patterns, shared data architecture, and replicable support models
A scalable global manufacturing platform
The client gained a digital plant foundation built to support both urgent manufacturing needs and longer-term manufacturing scale. The first phase demonstrated that a cloud-enabled MES environment could support regulated mRNA production when strategy, operations, and execution were tightly aligned.
The second phase extended that foundation into a more scalable digital manufacturing model. By moving more of the operating environment to the cloud and standardizing recipes, data structures, MES and DCS patterns, and support practices, the client could move beyond site-specific execution toward a manufacturing platform designed for global deployment.
The engagement also reinforced the importance of digital infrastructure integrity. To scale across sites, the architecture could not depend on one-off decisions made for a single product or one facility. It needed to be consistent, supportable, and adaptable enough to sustain shared manufacturing knowledge, operating practices, and data across the network.
Outcome
- A digital plant foundation serving both urgent needs and long-term scale
- Consistent, supportable architecture across the manufacturing network
From breakthrough science to transformative savings
The first phase helped the client move from scientific breakthrough to operational manufacturing execution at extraordinary speed. With a vaccine candidate developed in roughly two weeks, Stellix helped align the customer and its manufacturing partner around the digital plant strategy, systems, and execution path needed to quickly translate breakthrough science into a GMP manufacturing model.
That alignment enabled rapid execution. The first manufacturing phase was completed in approximately seven months, compared with a typical expectation of roughly two years. Stellix helped to create the focus, operating alignment, and plant-floor execution model needed to make this timeline possible.
The global scale phase extended the value of that foundation. Stellix supported development of a scalable enterprise MES approach for deployment across four sites in four countries with minimal cost and change. That approach helped the customer recognize more than $5.6 million in CapEx savings from individual site builds, while removing more than 7,000 hours of operator wait time per year.
Together, the work enabled the client to scale from a first-of-kind digital plant into a global manufacturing platform, accelerating product expansion, streamlining site deployment, and positioning the company for the next phase of digital-first biotech manufacturing.
Results
- First manufacturing phase completed in roughly seven months versus a typical two years
- More than $5.6M in CapEx savings across four sites in four countries
- Removed more than 7,000 hours of operator wait time per year
Bridging Vision and Reality
The future belongs to adaptive organizations
Let’s have a conversation about improving performance, strengthening operations, and updating systems to adapt as fast as your environment changes.